Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Heiq Plc LSE:HEIQ London Ordinary Share GB00BN2CJ299 ORD GBP0.30
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -0.71% 35.00 34.50 36.00 35.50 35.25 35.25 59,445 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 36.9 5.1 3.1 10.3 44

Heiq Share Discussion Threads

Showing 226 to 249 of 675 messages
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
19/3/2021
08:30
I think this share has the legs to fly over the next few months my biggest holding and adding .
2bluelynn
19/3/2021
07:49
The deal is a cracker. These are coming through at about 1 per week at the moment. Another new industry.
leafysuburb
19/3/2021
07:36
From today's RNS
"The two companies have signed a five year contract (US$8m in the first two years, at which point the contract is subject to renewal) which is expected to deliver US$30m of royalty revenue to the Company.."

HEIQ's 1 HY2020 revenue was US$30m

and from the Jan 2021 trading update

"The Company expects to report that revenue for FY 2020 exceeded market expectations. This was due to a robust performance delivered by HeiQ's core portfolio of products, including a particularly strong sales performance from its antimicrobial technology, HeiQ Viroblock, which was launched during the Period. Since then, it has been applied to over 1 billion facemasks and won the Swiss Technology Award in Q4 2020."

metis20
19/3/2021
07:19
pleased to announce that it has signed an Exclusive Licence and Chemicals Supply Agreement with ICP Industrial Inc, a division of ICP Group ("ICP"), the global leader in the development, application, and technical support of innovative thin film coatings which are applied to packaging used by the FMCG, pharmaceuticals and medical sectors.

The two companies have signed a five year contract (US$8m in the first two years, at which point the contract is subject to renewal) which is expected to deliver US$30m of royalty revenue to the Company ("the Minimum Exclusive Requirement") in exchange for exclusive worldwide rights to apply HeiQ Viroblock to coatings for printing processes such as commercial print, food, beverage and pharma packaging. ICP will market its products with the HeiQ Viroblock technology and trademarks to its downstream customers, which manufacture packaging products for some of the world's largest consumer brands. This will enable brand owners to market products packaged in materials with antimicrobial properties to consumers. The two companies are currently completing the product development, due to be finalized at the latest by 1st August 2021, following which the exclusivity period begins. HeiQ will supply ICP with HeiQ Viroblock, an antimicrobial technology proven to destroy over 99.99% of infectious viruses and bacteria within minutes, and will receive a percentage of ICP's net sales in the form of royalties, in line with its strategy to grow its high margin royalty and licensing business. The partnership enables HeiQ to bring its market leading antimicrobials and other HeiQ technologies into several new industry fields served by ICP.

HeiQ co-founder and CEO Carlo Centonze said:

"This multi-year agreement with a global print and packaging coating leader builds on our recent contract to apply HeiQ Viroblock to paint, demonstrating that HeiQ Viroblock and antimicrobial technology is becoming mainstream for all materials that we touch in our daily lives. It is with great pleasure that we team up with ICP Industrial Inc, a global leader which provides the print and packaging industry with advanced coating technologies. It is of paramount importance given that the global pandemic has shown that viruses can remain infectious on paper and cardboard for several days. These recent agreements relating to HeiQ Viroblock being adopted by businesses outside of the textile industry also highlight that our award-winning innovation has entered a new phase in its lifecycle and that the brand equity we have built as an innovation leader is delivering meaningful returns. Subject to a successful trial period, we believe that this royalty arrangement has the potential to deliver strong, high margin sales for HeiQ and to strengthen our brand equity significantly, through uptake by ICP's blue chip client base."

ICP Industrial's Division President Paul Grzebielucha said:

"We are excited to offer this new innovative life-saving technology to the print world. We have global reach under our brands of Nicoat, MinusNine and Hitech Coatings to provide this protection on billions of printed surfaces per year. This HeiQ Viroblock game changing technology for our industry and society has proven to be a superior solution that is currently available in the marketplace. HeiQ products have proven efficacy in terms of destroying infectious viruses in minutes rather than hours with an effective rate of 99.95%. ICP Industrial has always provided innovative solutions to the graphic arts and packaging segments while maintaining the highest level of customer and technical service in the industry. ICP Industrial is very excited about the partnership with HeiQ bringing this technology to market pro

jammytass
19/3/2021
07:06
That's a cracker!
davemac3
16/3/2021
11:41
Lee Cooper face masks with not only Virobloc but also Smart Temp technology
Https://www.amazon.co.uk/Lee-Cooper-V-block-Filters-Cooling/dp/B08FJ72KJQ/ref=sr_1_11?dchild=1&keywords=heiq+viroblock&qid=1615847716&sr=8-11

leafysuburb
14/3/2021
21:07
Berger Silk Breatheasy Https://www.bergerpaints.com/products/interior-wall-coatings/7/interior-emulsion/116/silk-breathe-easy
leafysuburb
11/3/2021
18:56
Its more likely market makers as sellers could gain a lot more for their shares. But if it gives me the opportunity to add further I will. All these deals add up and they are beginning to flow. Just read a good write up in Shares Magazine hinting at a lot more coming.
leafysuburb
11/3/2021
14:53
One of the more interesting pieces of news today and setting up for a sequence of further bullish pieces to hit the wires. Clearly the market is expecting this type of news and alot more.

Having watched this one abit closer recently, noted there are sellers in size who sell into all bullish news, and are at it again today so nothing as yet to change the more bullish dial from a short term perspective.

Nipped in and out of this one, but getting more and more tempted to tuck some of these away for the longer term. There are some tasty numbers being presented here and it looks a speculative possibility that the puzzle all comes together beautifully.

Could be abit early on the entry price with these big sellers feeding shares in. Need to see where the big buyers come in to offset these sell orders being worked, but certainly getting a little bullish tingle with this company.


A little bullish tingle?

Red flag alert, red flag alert!

Get Trident on even higher alert!

All imo
DYOR

sphere25
11/3/2021
09:11
It highlights the versatility of the product with Virobloc widening its appeal from textiles to other substances and materials. First mover status that will get them noticed. Holding firm to see if they snare Akzo Nobel who own Dulux paints or Hempel who own Crown paints.
leafysuburb
11/3/2021
08:57
"The agreement will deliver US$600,000 of revenue to HeiQ for the first year, during which Berger will have exclusivity in India, with potential for significant additional future revenues."

For an HEIQ income statement, see page of hTTps://heiq.com/wp-content/uploads/2020/12/2020.12_HeiQ-company-presentation_Investors.pdf

metis20
11/3/2021
07:25
RNS Berger paints
Plc
("HeiQ" or "the Company")

HeiQ Viroblock Partnership with Berger Paint

HeiQ (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has signed an agreement with global luxury paint provider Berger Paints India Ltd ("Berger"), among the largest 15 paint companies in the world. Berger will produce an innovative antiviral paint, Silk Breathe Easy, which will be powered by HeiQ Viroblock, proven to destroy over 99.99% of infectious viruses and bacteria.

The agreement will deliver US$600,000 of revenue to HeiQ for the first year, during which Berger will have exclusivity in India, with potential for significant additional future revenues. The exclusivity term also has the potential to be extended by HeiQ.

This partnership is in line with HeiQ's strategy to innovate in and beyond textiles, eventually becoming a global leader in materials innovation. This is the first time that HeiQ Viroblock, which won the prestigious Swiss Technology Award in 2020, will be used in the paints & coatings industry, opening up an exciting new market opportunity for HeiQ, which is dominated by Akzo Nobel, PPG and Sherwin Williams.

Silk Breathe Easy is a luxury interior paint designed to give walls a rich appearance, to significantly reduce pollution and to protect by preventing surface transmission of diseases caused by bacteria and viruses. It is designed to enhance hygiene and reduce the risk of contamination in households, public and semi-public spaces. It can also be used in hygiene-sensitive environments such as surgical theaters and other medical and healthcare facilities. Formulated with 100% acrylic emulsions and vibrant pigments, it has low volatile organic compound ("VOC") and has formaldehyde reduction abilities.

HeiQ co-founder and CEO Carlo Centonze said:

"This contract demonstrates the significant market opportunity for HeiQ Viroblock beyond textiles, and with exclusivity only granted in India, there is potential to roll out the application of our award-winning antiviral technology in paint and coatings to different partners and territories. We are thrilled to have moved into this new US$150 billion material market alongside such a prestigious brand, which has built a strong industry reputation for being a first mover in establishing a number of trendsetting innovations. This builds on the success we have already experienced to date with our innovation, having already 'viroblocked' over a billion textile products since launching it a year ago.

jammytass
11/3/2021
07:12
RNS Berger paints
jammytass
04/3/2021
09:30
“We are particularly excited about Chrisal’s symbiotic technology solution for healthcare and hospitals for which full clinical results are due to be published imminently in a leading journal”
leafysuburb
03/3/2021
16:54
Broken key levels with the sellers in size at 204-205p from recent days now appearing to have been cleared on the back of today's bullish news. However, as per the previous post, there sure did appear to be some suspect buying in the afternoon yesterday.

<--- Been doing this a while, notice things :-)

Some SCSW for sure (though the bulk of that is always the Monday following the release and then some into Tuesday morning where it can fade off), some folk following other buying but surely not all can be explained by the errr...material pick up of buying in the afternoon.

It happens, just saying.

Not fully up to speed with this one on the fundamentals. It looks a speculative one that appears to be expensive but with so many avenues and a big market to tackle, it could double and still look cheap.

Piggybacking off the recent buying here, but could be one of those just to tuck away and leave for a few years but who can do stuff like that anyway? That's a skill in itself!

All imo
DYOR

sphere25
03/3/2021
12:12
This mornings deal with Chrisal is a good earnings enhancing deal that fits like a glove with HeiQ and its growth and they are targeting cross selling and synergies with the bottling plant definitely an attraction. The structure of the deal with 51% and the controlling interest purchased is also good for the everyday running of the company is being left to the present Management but The CEO and other Member of the HeiQ Board will join The Chrisal Board to participate and steer things at Board level and without distraction from any other projects. All paid for as well.
leafysuburb
03/3/2021
10:58
this guy has a good track record and talks about Heiq from about 30:25
htTps://www.youtube.com/watch?v=HoTULGVSEvM&t=768s

davemac3
03/3/2021
08:37
I am surprised the announcement has had little effect on share price
iandippie
03/3/2021
08:22
Should get good press tomoz

And upgrade

euromedic
03/3/2021
07:10
3 March 2021

HeiQ Plc
(

Acquisition of 51% of Industrial Biotech Business, Chrisal

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has signed an agreement to acquire 51% of the share capital and voting rights of Chrisal N.V., Belgium ("Chrisal", "the Acquisition"). The Acquisition is for a consideration of €7.5 million, with €5.0 million payable in cash and €2.5 million through the issue of 1,101,928 new ordinary shares by HeiQ. On completion, Chrisal will be renamed HeiQ Chrisal.

Chrisal is a profitable industrial biotechnology company and a leader in innovative ingredients and consumer products that incorporate the benefits of probiotics and synbiotics. It has 120 products within its three technology platforms that create healthy and sustainable microbial ecosystems. The application of its proprietary technology includes cosmetics, personal care, textiles, wound dressings, water purification, air treatment and cleaning products. Chrisal has recently developed a synbiotic interior cleaner, Synbio®, for healthcare and hospitals, a project sponsored by The Gates Foundation. Early results have indicated Synbio® cleaners to be equal to disinfectants and detergents but without bacterial resistance downsides, while offering enhanced cleaning performance.

The Acquisition is aligned with HeiQ's strategy of becoming a global leader in materials innovation. It also solidifies HeiQ's position as a profitable and fast-growing pioneer in the $24 billion global textile chemicals market. HeiQ already directly serves the $10 billion antimicrobial textile market with its HeiQ Viroblock and HeiQ Pure technology platforms and the Acquisition will strengthen its presence with a complementary probiotic platform while enabling it to enter the new adjacent and lucrative markets of surface hygiene treatment, water purification and probiotic personal care.

Additional Highlights
· Chrisal recorded revenue of €5.5 million for the 12 months to 31 December 2020, an increase of 62% compared to 2019, and an operating profit of €1.6 million (28.9%) - unaudited.

· Chrisal has over 500 commercial customers in 25 countries, including hospitals, food and cosmetic manufacturers, presenting HeiQ with compelling cross-selling opportunities for its existing core product range. Chrisal will benefit from HeiQ's extensive customer and distribution network, as well as its marketing prowess.

· Chrisal customers include Q viva, Ahava, Atena-Alfa, Probilife, Sonax, Woellner and Greenspeed

· The Acquisition includes a bottling facility in Belgium. This is an important infrastructure requirement for HeiQ's ambitions in functional textile aftercare and other fields.

· The current Chrisal President and Founder Corrie Gielen and its CEO/CTO Dr. Robin Temmerman will continue to lead the business, supported by the existing Chrisal team.

· HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors and will explore further synergies over the course of 2021.

· HeiQ Chrisal will be responsible for the creation, production and commercialisation of its products, with HeiQ acting as its corporate service hub and extended commercialization arm.

· Chrisal's patented technology carries the prestigious EU Ecolabel, a label of excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle.

HeiQ co-founder and CEO Carlo Centonze said:

"The acquisition of a majority stake in Chrisal brings multiple benefits to HeiQ and its shareholders. HeiQ Chrisal will provide us with revenue from other fast-growth markets adjacent to those we serve already, as well as exciting cross-selling opportunities for our and their existing core product range. The acquisition will progress our direct to consumer offer and enlarges our product offering to hygiene-sensitive environments, such as the healthcare sector.

"Chrisal's technology platform includes an anti-allergen effect for mattresses and bedding, microbial and viral protection for surfaces, anti-inflammatory effects in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection to replace the resistance-creating antibiotics in animal husbandry. We are particularly excited about Chrisal's synbiotic technology solution for healthcare and hospitals for which full clinical results are due to be published imminently in a leading journal.

"HeiQ is increasingly becoming more than a textile technology company; we are innovating materials more broadly. This acquisition of a leading probiotics business is aimed at making HeiQ a leader in probiotic innovation, positioning us well to serve many lucrative segments of this fast growth USD 50 billion market.

"Chrisal's culture of entrepreneurship, people empowerment, sustainability, innovation and lean processes are a perfect match with HeiQ. I expect this partnership to become a great success and we will look forward to working closely with Corrie, Robin and the rest of the Chrisal team."

Corrie Gielen, President of Chrisal commented:
"For 30 years Chrisal has built on new technologies to improve our world in a sustainable way. With our latest patented Synbio® technology we have found the best solution to strengthen products, people and our environment. We are confident that the new partnership with HeiQ will bring us the additional competences and network needed to globalize this beautiful and groundbreaking technology. Together we combine the best of nature with the latest in science to make the difference for a better world."

Further Information on Chrisal:

Chrisal is an industrial biotechnology leader in prebiotic, probiotic and synbiotic technologies and products. With its 120 products, Chrisal serves commercial and consumer customers operating in the markets of cosmetics, personal care, textiles, wound dressings, water and air purification and cleaning solutions for hospitals and animal husbandry. Early results from clinical trials for Chrisal's patented Synbio®, an active synbiotic surface cleaner, suggest that it could be the next generation technology to probiotic surface cleaners, such as Reckitt Benckiser's VEO. Chrisal technology carries the prestigious EU Ecolabel, a label of environmental excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle.

The industrial biotech acquisition will provide HeiQ access to the technology platform of prebiotics, probiotics and postbiotics for bio-based odor & stain control for carpet & footwear, anti-allergen effect in mattress and bedding, microbial and viral protection for surfaces, anti-inflammatory effect in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection replacing the resistance-creating antibiotics in animal husbandry. With this strategic acquisition HeiQ enters the broader market of surface management and accesses a bio-based green complementary technology platform to its antimicrobials.

Chrisal's 120 products strengthen HeiQ's global product offering and will facilitate HeiQ's existing technology platforms into new markets.

Chrisal has a large, efficient manufacturing footprint in Lommel, Belgium and brings into the HeiQ group the strategic capability of bottling, a step required for HeiQ's B2C products ambitions in functional textile aftercare and other fields. Chrisal also includes a microbiology and molecular diagnostics lab for R&D and QC activities.

HeiQ Chrisal, the new corporate name for Chrisal, will continue to be led by President and Founder Corrie Gielen, its CEO/CTO Dr. Robin Temmerman as well as the entire Chrisal team. The entrepreneurial drive will be strengthened by HeiQ's Group support functions in Rapid & Deep R&D, Branding & Marketing, Regulatory and Compliance as well as Commercialisation. HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors.

HeiQ Chrisal will be responsible for the creation, production and commercialization of its products, with the HeiQ Group acting as its corporate service hub and extended commercialization arm. Together, the newly enlarged Board will explore further synergies over the course of 2021.

Issue of Equity and Total Voting Rights

The Company will issue 1,101,928 new ordinary shares ("Consideration Shares") to the sellers of Chrisal, at a price of 1.9596p per share, which is the average 5 day closing price prior to signing, in order to part satisfy the consideration due. Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission").

It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 9 March 2021.

Following Admission, the total number of Ordinary Shares in issue will be 126'993'832 and the total number of voting rights will therefore be 126'993'832. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information.

For further information, please contact:

HeiQ Plc

jammytass
02/3/2021
17:38
Sphere252 Mar '21 - 16:05 - 214 of 215
0 1 0
Is the bulk of today's buying on the back of that? Is that new?

old news see 188

davemac3
02/3/2021
16:11
news tomorrow? Buying into the close
nobilis
02/3/2021
16:05
Is the bulk of today's buying on the back of that? Is that new?
sphere25
02/3/2021
13:30
hxxps://www.planetalking.net/sanitisation


That looks like Heiq kit

If they announce a contract in an RNS it would send this through the 52-wk high of 250p

nobilis
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
Your Recent History
LSE
HEIQ
Heiq
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 05:47:28